| 초록 |
Due to their unique biochemical and biophysical characterization, tunable surface modification, and controllable size and shape, biodegradable polymer-based nanoparticles have been widely utilized for different biomedical applications, such as drug and gene delivery, imaging purposes, and detection & diagnosis of diseases, etc. Tumor metastasis, immunotherapy and treatment resistance as clinical obstacles were broadly explored with different molecular mechanisms for clarification, respectively. There is still no significantly clinical improvement to these significant barriers for efficient tumor cure so far. Compared to traditional drug delivery systems, nano-systems have greater potential in many areas, such as multiple targeting functionalization, combined drugs delivery, longer circulation time and systemic control release. Some of these have been translated from the bench to clinical application and approved by the Food and Drug Administration (FDA) for treatment of various cancerous diseases. With further development of biocompatible nanoformulations, it might be possible to design even more promising multiple-responsive nano-systems synergistic for combined improved bioavailability/druggability and efficient cancer therapy in the future. Nanotechnology-based pharmaceutical development is expected to bring new hope for cancer treatment by enhancing anticancer drug efficacy, overcoming drug resistance and reducing drug toxicity. This presentation describes the characteristic features of tumor resistance to classical chemotherapy and their mechanisms with the aid of biodegradable polymer-based nanoparticles for the development of newer pharmaceutical systems to overcome adoptive treatment tolerance in vitro and in vivo. |
